Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Infectious Disease·MeSH: Fibrosis
1 drug in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)
DrugCompany
Pegozafermin89bio, Inc. (ETNB)

Frequently asked questions

How many drugs are in development for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis?

BioSniper tracks 1 drug in development for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis across 1 company.

How many clinical trials target Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis?

There are 1 clinical trial targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis tracked by BioSniper.

Deep-dive into Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis — Drugs in Development & Clinical Trials | BioSniper